Doctors' kickbacks and related kickbacks account for two-thirds of the whole drug, or even higher. For example, the price of treating heart disease in a hospital is a box in 20 yuan. But if the doctor sells a box on his behalf, he can get a rebate from 9 yuan and pay it monthly, which is very creditable. It can be seen that the doctor's rebate has a high weight in the drug price. Similar to the doctor's rebate, there is also the hospital pharmacy department-if you don't give money, you won't buy the medicine from your manufacturer. As for the specific proportion of pharmacies in this respect, it depends on how manufacturers, doctors and pharmacies coordinate.
Production costs, raw materials and production line costs, corporate repayment and operating costs. This part generally accounts for one third.
Corporate profits: negligible. Even those pharmaceutical companies that seem to have high profits, most of their profits are still covered up by kickbacks from many doctors.
Doctors take kickbacks, mainly because of the bad atmosphere brought by foreign pharmaceutical companies. The medical institutions in the United States are completely different from those in China. Private doctors in the United States take kickbacks from manufacturers in order to increase profits. This is reasonable in the United States, but after foreign pharmaceutical companies came to China, in order to quickly start the market, they took advantage of the neglect and tolerance of foreign investment by China's national regulatory agencies and took improper measures to enter the China medical industry market.
Many domestic pharmaceutical companies have been crushed. Subsequent pharmaceutical companies had to take a similar approach under competition.
Generally speaking, pharmaceutical companies in China invest in building new production lines to develop a new drug. Three to five years later, they paid patent fees, advertisements, kickbacks and bank loans, but they didn't earn anything except a dilapidated production line-as long as the steel is broken and it doesn't fall apart, it is the fixed assets of pharmaceutical companies, so they can mortgage it, borrow it, go to a new production line and buy patent fees for new drug research and development ... This is a pharmaceutical company in China.